Department of Pediatrics and Children's Diabetology, Faculty of Medical Sciences in Katowice, Medical University of Silesia, Silesia, Poland.
Maria Sklodowska-Curie Bialystok Oncology Center, Ogrodowa 12 str., 15-027, Bialystok, Poland.
Acta Diabetol. 2021 Aug;58(8):1101-1110. doi: 10.1007/s00592-021-01701-1. Epub 2021 Mar 20.
The novel coronavirus disease 2019 (COVID-19) has spread worldwide since the beginning of 2020, placing the heavy burden on the health systems all over the world. The population that particularly has been affected by the pandemic is the group of patients suffering from diabetes mellitus. Having taken the public health in considerations, we have decided to perform a systematic review and meta-analysis of diabetes mellitus on in-hospital mortality in patients with COVID-19.
A systematic literature review (MEDLINE, EMBASE, Web of Science, Scopus, Cochrane) including all published clinical trials or observational studies published till December 10, 2020, was performed using following terms "diabetes mellitus" OR "diabetes" OR "DM" AND "survival" OR "mortality" AND "SARS-CoV-2" OR "COVID-19".
Nineteen studies were included out of the 7327 initially identified studies. Mortality of DM patients vs non-DM patients was 21.3 versus 6.1%, respectively (OR = 2.39; 95%CI: 1.65, 3.64; P < 0.001), while severe disease in DM and non-DM group varied and amounted to 34.8% versus 22.8% (OR = 1.43; 95%CI: 0.82, 2.50; P = 0.20). In the DM group, the complications were observed far more often when compared with non-DM group, both in acute respiratory distress (31.4 vs. 17.2%; OR = 2.38; 95%CI:1.80, 3.13; P < 0.001), acute cardiac injury (22.0% vs. 12.8%; OR = 2.59; 95%CI: 1.81, 3.73; P < 0.001), and acute kidney injury (19.1 vs. 10.2%; OR = 1.97; 95%CI: 1.36, 2.85; P < 0.001).
Based on the findings, we shall conclude that diabetes is an independent risk factor of the severity of COVID-19 in-hospital settings; therefore, patients with diabetes shall aim to reduce the exposure to the potential infection of COVID-19.
自 2020 年初以来,新型冠状病毒病 2019(COVID-19)已在全球范围内传播,给全世界的卫生系统带来了沉重的负担。受大流行影响特别大的人群是患有糖尿病的患者群体。考虑到公共卫生,我们决定对 COVID-19 住院患者的糖尿病与院内死亡率进行系统评价和荟萃分析。
对截至 2020 年 12 月 10 日已发表的所有临床试验或观察性研究进行了系统文献检索(MEDLINE、EMBASE、Web of Science、Scopus、Cochrane),使用以下术语进行检索:“糖尿病”或“糖尿病”或“DM”和“生存”或“死亡率”和“SARS-CoV-2”或“COVID-19”。
在最初确定的 7327 项研究中,有 19 项研究符合纳入标准。与非糖尿病患者相比,糖尿病患者的死亡率为 21.3%对 6.1%(OR=2.39;95%CI:1.65,3.64;P<0.001),而糖尿病和非糖尿病组的严重疾病分别为 34.8%和 22.8%(OR=1.43;95%CI:0.82,2.50;P=0.20)。在糖尿病组中,与非糖尿病组相比,并发症更为常见,急性呼吸窘迫发生率分别为 31.4%和 17.2%(OR=2.38;95%CI:1.80,3.13;P<0.001)、急性心脏损伤发生率分别为 22.0%和 12.8%(OR=2.59;95%CI:1.81,3.73;P<0.001)和急性肾损伤发生率分别为 19.1%和 10.2%(OR=1.97;95%CI:1.36,2.85;P<0.001)。
基于这些发现,我们可以得出结论,糖尿病是 COVID-19 住院患者严重程度的独立危险因素;因此,糖尿病患者应努力减少接触 COVID-19 的潜在感染。